Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer

2020 ◽  
Vol 40 (2) ◽  
pp. 901-913
Author(s):  
GEORGIOS IOANNIDIS ◽  
CHARA PAPADAKI ◽  
ELENI LAGOUDAKI ◽  
MARIA TZARDI ◽  
MARIA TRYPAKI ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Messenger Rna ◽  
Small Cell ◽  
Rna Expression ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Predicting Outcome

scholarly journals Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

2019 ◽  
Vol 14 (2) ◽  
pp. 304-310 ◽  
Author(s):  
Niki Karachaliou ◽  
Jillian Wilhelmina Paulina Bracht ◽  
Manuel Fernandez Bruno ◽  
Ana Drozdowskyj ◽  
Ana Gimenez Capitan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Messenger Rna ◽  
Small Cell ◽  
Rna Expression ◽  
Small Cell Lung

scholarly journals Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004 ◽  
Vol 10 (4) ◽  
pp. 1318-1325 ◽  
Author(s):  
Rafael Rosell ◽  
Kathleen D. Danenberg ◽  
Vincente Alberola ◽  
Gerold Bepler ◽  
Jose Javier Sanchez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Ribonucleotide Reductase ◽  
Messenger Rna ◽  
Small Cell ◽  
Rna Expression ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Osteopontin But Not Osteonectin Messenger RNA Expression Is a Prognostic Marker in Curatively Resected Non-Small Cell Lung Cancer

2004 ◽  
Vol 10 (5) ◽  
pp. 1588-1596 ◽  
Author(s):  
Sylke Schneider ◽  
JiMin Yochim ◽  
Jan Brabender ◽  
Kazumi Uchida ◽  
Kathleen D. Danenberg ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Prognostic Marker ◽  
Cell Lung Cancer ◽  
Messenger Rna ◽  
Small Cell ◽  
Rna Expression ◽  
Small Cell Lung

Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer

2002 ◽  
Vol 29 (3 Suppl 12) ◽  
pp. 10-16 ◽  
Author(s):  
Angela Davies ◽  
David R. Gandara ◽  
Primo Lara ◽  
Zelanna Goldberg ◽  
Peter Roberts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iii ◽  
Advanced Stage ◽  
Therapeutic Approaches ◽  
Small Cell Lung

scholarly journals Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

2017 ◽  
Vol 35 (5) ◽  
pp. 529-535 ◽  
Author(s):  
Cathy J. Bradley ◽  
K. Robin Yabroff ◽  
Angela B. Mariotto ◽  
Christopher Zeruto ◽  
Quyen Tran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Antineoplastic Agents ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Medicare Data ◽  
Outcome Information ◽  
New Diagnosis

Purpose Multiple agents for advanced non–small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis. Results During the 12-year study period, a marked shift in treatment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine (5.7%; all P < .05). The average total days on therapy increased by 5 days (from 103 to 108 days). Patients who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v 75 days for those who did not receive these agents). Approximately 44% of patients received antineoplastic agents in the last 30 days of life throughout the study period. Acute inpatient spending declined (from $29,376 to $23,731), whereas outpatient spending increased 23% (from $37,931 to $46,642). Median survival gains of 1.5 months were observed. Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in survival and total Medicare spending. More precise outcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

scholarly journals 631. Phase 1/2 Trial of Autologous Tumor Mixed with an Allogeneic GVAX® Immunotherapy in Advanced Stage Non-Small Cell Lung Cancer

2006 ◽  
Vol 13 ◽  
pp. S243
Author(s):  
John Nemunaitis ◽  
Thierry Jahan ◽  
Helen Ross ◽  
Daniel Sterman ◽  
Donald Richards ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase 1 ◽  
Small Cell ◽  
Autologous Tumor ◽  
Advanced Stage ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document